ZYME (Zymeworks Corp) Long-Term Debt

Corporate emblem and logo of Zymeworks Biopharmaceuticals (ZYME)

Strategic risks for Zymeworks Inc. (ZYME) are linked to an inflated rate for a single drug and research costs, with the indicator standing at 0.28. Zymeworks Inc. (ZYME) is developing multispecific antibodies, relying on the support of major partners to advance zanidatamab. This price chart reflects the asset's dynamics, whose resilience is based on technology licensing and the diversification of oncology projects to secure stable royalties.

ZYME (Zymeworks Corp) Company Long-Term Debt history from 07/04/2022 to 10/28/2026

Financial and market metric breakdowns for Zymeworks Corp (ZYME)

- price and consensus price forecast:
Stock Quotes zymeworks.com|ZYME - Price Target Chart
- market capitalization data:
Market Value Zymeworks|ZYME - Total Company Value
- book capitalization data:
Net Assets per Single Share Zymeworks|ZYME - Company Book Value|Market-to-Book Ratio zymeworks.com|ZYME - Company Total Assets
- debt and liquidity data:
Debt to Capital Ratio Zymeworks Inc.|ZYME - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Zymeworks Biopharmaceuticals|ZYME - Company Total Debt|Debt to Net Assets Ratio Zymeworks|ZYME - Company Long-Term Debts|Short-Term Debt Volume Zymeworks
Comprehensive company analysis:ZYME (zymeworks.com)
Mass-produced product of Zymeworks

Long-term debt aggregates loan and bond obligations with maturities exceeding one year, allowing for an assessment of the debt load and the cost of borrowed capital. By analyzing the value of the firm's long-term borrowings, an investor determines the financial stability of Zymeworks Inc. (ZYME), which is bolstered by the cyclical independence of cancer immunotherapy and stable demand for treatment regardless of market turmoil.

Competing companies

immunitybio.com - Company Long-Term Liabilities|IMCR (Immunocore) - Company Long-Term Debt|JANX: Long-Term Debt|Arcus Bio (RCUS) - Company Long-Term Debt|TNGX (Tango Therapeutics Corp) - Company Long-Term Debt|Company Long-Term Debt IOVA (Iovance Biotherapeutics)|Long-Term Debt immatics.com|XNCR: Company Long-Term Debts|Long-Term Indebtedness Compass Therapeutics Inc CMPX|REPL: Company Long-Term Liabilities|LYEL - Long-Term Debt|Company Long-Term Liabilities Innate Pharma S.A. (IPHA)|PYXS - Company Long-Term Loans and Borrowings|cgen.com - Company Long-Term Debts|IOBT (IO Biotech Inc) - Long-Term Debt Volume|Company Long-Term Debt STRO|Company Long-Term Liabilities INKT|Company Long-Term Debt HOWL (Werewolf Therapeutics)|Company Long-Term Liabilities immixbio.com IMMX|Company Long-Term Liabilities ALXO (ALX Oncology Holdings)|cuebiopharma.com - Company Long-Term Debts|PDS Biotechnology Corp (PDSB) - Company Long-Term Debt|SONN: Company Long-Term Indebtedness|Company Long-Term Debt MAIA|Long-Term Debt liminatuspharma.com|LAVA Therapeutics NV - Company Long-Term Liabilities|Long-Term Indebtedness NextCure Inc (NXTC)|Company Long-Term Liabilities Leap Therapeutics, Inc.|Amount of Long-Term Liabilities intensitytherapeutics.com (INTS)|Company Long-Term Debts Sensei Biotherapeutics, Inc.|Company Long-Term Loans and Borrowings therivabio.com TOVX|GRTS (Gritstone Bio) - Company Long-Term Debts|KA: Long-Term Debt|Company Long-Term Debt NexImmune Corp NEXI|Turnstone Biologics Corp. (TSBX) - Company Long-Term Loans and Borrowings|VCNX (Vaccinex, Inc.) - Company Long-Term Debts|Company Long-Term Debts HARP